Infection with Omicron variant generates neutralizing antibodies to BA.1 and BA.2 sub-

lineages and induces higher levels of cross-neutralizing antibodies to Delta variant

Short Title: Omicron infection induces antibodies to Delta variant

Janmejay Singh[1*] Heena Shaman[1*], Anbalagan Anantharaj[1*], Balwant Singh[1], Kamal Pargai[1],

Parveen Kumar[1], Partha Chattopadhyay[2,3], Priti Devi[2,3], Ranjeet Maurya[2,3], Pallavi Mishra[2],

Namrata Kahlon[4], Anil Kumar Pandey[4], Rajesh Pandey[2] and Guruprasad R. Medigeshi[1#]

1: Bioassay Laboratory, Translational Health Science and Technology Institute, Faridabad,

Haryana. INDIA.

2: INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of

Genomics and Integrative Biology, Delhi, INDIA.

3: Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.

4: Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana,

INDIA.

* These authors contributed equally

 # Corresponding author:

Guruprasad R. Medigeshi, PhD

Translational Health Science and Technology Institute,

P.O. Box # 4, Faridabad-Gurgaon Highway,

Faridabad 121001. INDIA.

Tel: +91-0129-2876311.

Email: gmedigeshi@thsti.res.in

ABSTRACT

The Omicron variant of SARS-CoV-2 is capable of infecting unvaccinated, vaccinated and

previously-infected individuals due to its ability to evade neutralization by antibodies. With three

sub-lineages of Omicron emerging in the last four months, there is inadequate information on the

quantitative antibody response generated upon natural infection with Omicron variant and

whether these antibodies offer cross-protection against other sub-lineages of Omicron variant.

We show that both binding and neutralizing antibodies wane by >50% in six months in study

participants with hybrid immunity. Omicron infection in a subset of individuals led to a

significant increase in binding and neutralizing antibodies to BA.1 and BA.2 sub-lineages of

Omicron. The levels of neutralizing antibodies were higher against the Delta variant as compared

to the Omicron sub-lineages. These data suggest that Omicron infection elicits neutralizing

antibodies that can cross-react with other sub-lineages of Omicron and other variants of concern

in people with hybrid immunity.

Keywords: COVID-19; RBD; Neutralizing antibodies; FRNT; ELISA; Omicron; Delta

INTRODUCTION

Close to 17 million cases of COVID-19 was reported from India during the second wave in mid-2021 which was attributed to the deadly Delta variant of SARS-CoV-2 which accounted for close to 40% of the >500,000 deaths in this pandemic. Contrary to this, the current third wave which is on the decline and attributed to the Omicron variant of SARS-CoV-2 has resulted in milder symptoms and around 40,000 people have succumbed to the infection (https://www.worldometers.info/coronavirus/country/india/).

In addition to the less virulent Omicron variant (1), increased vaccination coverage and hybrid immunity may have contributed to reduced impact of third wave in India. Most adults above the age of 18 in India have received at least one dose of vaccination and have also been infected naturally during the second wave of SARS-CoV-2 pandemic. However, there are very few reports from India on the effect of prior humoral immunity from natural infection on vaccine-induced antibody responses and there is no data on the impact of hybrid immunity on response to Omicron infection. We assessed the neutralization titers of antibodies prior to and after natural infection with Delta variant in a cohort of subjects who had received a single dose of ChAdOx1 nCoV-19 vaccination in mid 2021. We measured the titers of binding and neutralizing antibodies after one or two doses of vaccination in participants who were with or without prior natural infection. We measured the antibody levels six months post vaccination and also after natural infection with Omicron variants using a new focus reduction neutralization test (FRNT) that we established for Omicron variant. Our results indicate that despite hybrid immunity, most individuals got infected with Omicron variant and natural exposure to Omicron variant led to higher levels of boosting of antibodies to Delta variant and also led to generation of cross-neutralizing antibodies for both BA.1 and BA.2 sub-lineages of the Omicron variants.

RESULTS

A single dose of vaccination boosts antibody levels in seropositive individuals

Less than 10 % of the Indian population had received one dose of COVID-19 vaccine at the

onset of second wave of COVID-19 in April 2021 and recent reports including results from our

group attribute this sudden spike in cases to the capacity of the virus to escape neutralization by

antibodies thereby compromising vaccine effectiveness and increased infectivity and

transmission of Delta variant (2-6). To further understand how vaccination and neutralizing

antibodies impact Delta variant and disease outcomes, we enrolled 25 subjects (Median age 31; 9

Female, 16 Male) out of which 20 subjects received their first dose of ChAdOx1 nCoV-19

vaccine and 18 of the 20 subjects consented for collection of blood samples three weeks after the

first dose of vaccination to quantitate serum antibodies against the receptor-binding domain

(RBD) of SARS-CoV-2 spike protein by quantitative ELISA. 5 subjects were non-vaccinated

controls. 8 of the 20 vaccinated subjects were seropositive at least three months prior to receiving

the first dose of vaccine. Geometric Mean Titers (GMT) of antibodies against the RBD of SARS-

CoV-2 spike protein in subjects with no prior history of COVID-19 infection was 58.9 binding

antibody units (BAU)/ml (95% CI: 25.3 - 137.3) as compared to 562.5 BAU/ml (95% CI: 123.9 -

2555) in subjects who had prior history of COVID-19 clearly demonstrating a ten-fold higher

levels of antibodies after one dose of vaccination (Fig. 1A). The GMT of antibodies in non-

vaccinated subjects was 8.6 BAU/ml (95% CI: 2 - 36.7) which was below the limit of

quantitation (12 BAU/ml) of the assay. As the second wave of COVID-19 coincided with the

study, 8 of the 25 subjects showed symptoms of COVID-19 and were tested positive by RT-

PCR. Interestingly, all the eight subjects had no history of COVID-19 infection before the

second wave and six of the eight subjects had received the first dose of ChAdOx1 nCoV-19

vaccine. The GMT of RBD antibodies prior to second wave infection in subjects who tested

COVID-19 positive was 22.5 BAU/ml (95% CI: 7.7 - 65.6) whereas the same was 194.4

BAU/ml (95% CI: 66.0 - 572.2) in subjects who remained uninfected or did not show any

symptoms of infection (Fig. 1B). All the eight subjects who were infected showed mild to

moderate symptoms and recovered after home isolation. These results show a strong association

between high levels of pre-existing RBD antibody titers and protection from infection or from

severe disease. This also suggests that natural infection before the second wave of COVID-19 (in

India) or even one dose of vaccine conferred protection from reinfection or severe disease in this

age group. We performed paired analysis for GMT of RBD antibodies prior to and after second

wave infection. Mean titers of antibodies in individuals who were COVID-19 positive in the

second wave increased from 22.5 BAU/ml (95% CI: 7.7 - 65.6) to 629.5 BAU/ml (95% CI:

219.5 - 1805) (Fig. 1C). We did not observe any significant change in antibody levels in

individuals who were not infected during the second wave. The antibody levels in these subjects

was 135.4 BAU/ml (95% CI: 46.2 - 396.9) which showed a declining trend with a titer of 80

BAU/ml (95% CI: 29.6 - 216.8) in the second bleed further demonstrating lack of exposure to

SARS-CoV-2 in these subjects (Fig. 1D).

Cross-neutralizing antibodies after vaccination or infection with Delta variant

The second wave of COVID-19 infection between March-May 2021 in India was mostly due to

B.1.617.1 and B.1.617.2 variants (7). We sequenced viral RNA from three of the positive

samples in our study and found them to be either B.1.617.1 or B.1.617.2. To verify the

neutralization potential of antibodies in the serum samples of subjects from this study, we

estimated 50% virus neutralization titers from pre- and post-infection serum using a FRNT assay

against the B.6, B.1.1.7 and B.1.617.2 lineages respectively (5,8). We first analyzed the effect of

single dose vaccination with ChAdOx1 nCoV-19 in subjects who had the history of prior

COVID-19 infection. Samples collected three weeks after first dose of vaccination showed that

the GMT for virus neutralization were higher by over one order of magnitude in individuals with

prior history of COVID-19 infection as compared to those with no prior history of COVID-19

infection (Table 1) suggesting that a single dose of vaccination boosts the antibody titers due to T

and B-cell memory responses. In order to further verify if the pre-infection antibody titers

correlate with protection from infection or severe disease, the data was analyzed based on the

infection status in the second wave of COVID-19 which followed few days after the collection of

first bleed. The pre-infection GMT for virus neutralization of subjects who got infected in the

second wave (n=8) was 71 (95% CI: 42, 118), 44 (95% CI: 25, 78) and 34 (95% CI: 34, 46) for

B.6, Alpha and Delta variants respectively (Fig. 2A-C) (Supplementary Table S1). The GMT of

neutralizing antibodies in the first bleed after one dose of vaccination in subjects who were

seronegative prior to vaccination and were protected from SARS-CoV-2 infection during the

second wave was 185 (95% CI: 129, 265), 67 (95% CI: 46, 99) and 83 (95% CI: 40, 174) for

B.6, Alpha and Delta variants respectively (Supplementary Table S2). This suggests that the

GMT for virus neutralization between 34 to 83 is required to prevent infection from Delta variant

which is within the estimated values from mathematical models (9). As expected, participants

with hybrid immunity were protected from SARS-CoV-2 infection during the second wave and

had very high levels of neutralizing antibodies (Supplementary Table S3). While the neutralizing

antibody levels clearly showed a steep increase in participants who got infected during the

second wave (Figure 2 A-C), the same remained unchanged in those who were protected from

infection during the second wave (Figure 2D-F and Supplementary Table S2 and S3). Exposure

to Delta variant led to generation of neutralizing antibodies for both Alpha variant and SARS-

CoV-2 B.6 lineage which was circulating in 2020 (Figure 2A-C). We were able to obtain a

follow-up sample six months after two dose vaccination from 14 of our study participants. RBD-

ELISA antibody titers reduced significantly (P<0.05) from a GMT of 237 (95% CI: 97, 584) to

76 (95% CI: 40, 146) within six months (Figure 2G). Similarly, the neutralizing antibody titers

for Delta variant reduced by two-fold from a GMT of 232 (95% CI: 100, 538) to 100 (66, 154)

but this reduction was not significant (Figure 2H). However, we have shown recently that

waning antibody titers and lack of neutralizing antibodies to the Omicron variant in majority of

the people has contributed to the onset of third wave (8).

A fluorescence-based FRNT assay for Omicron variant

While this study was in progress Omicron (B.1.1.529) emerged as a new variant of concern

(VoC) with over 30 substitutions in the spike region alone and multiple studies demonstrating

neutralization escape (8,10,11). We attempted isolation of Omicron variants by inoculating both

Vero E6 and Calu-3 cells with diagnostic samples obtained from RT-PCR positive

nasopharyngeal/oropharyngeal swabs. We were able to isolate BA.1 sub-lineage of Omicron

variant only in Calu-3 cells which was verified by whole genome sequencing. We performed

conventional plaque assays with the virus stocks using both Calu-3 and Vero E6 cells and found

delayed and small plaque formation in Calu-3 cells as compared to Delta variant (Figure 3A).

However, unlike the Delta variant, the Omicron variant did not produce plaques up to 48 h post-

infection in Vero E6 cells. As Calu-3 cells are slow-growing and plaque assays are not amenable

for high-throughput neutralization assays, we first tested the ability of Omicron variant to form

infectious foci by antibody staining with anti-spike and anti-nucleocapsid antibodies in Vero E6

cells. While the Delta variant formed clear discernable infectious foci with both the antibodies,

the same was less distinct with anti-spike antibodies for Omicron variant although it was

countable by the plate reader (Figure 3B). Staining with nucleocapsid antibodies produced better

foci in the case of Omicron variant but the quality of foci was not comparable with Delta variant

(Figure 3B). We next tested secondary antibodies conjugated with fluorescent dye instead of

horseradish peroxidase enzyme (HRP) and visualized the infectious foci in fluorescence mode.

Use of fluorescence-based detection was far superior to HRP-based enzyme-substrate detection

for the Omicron variant (Figure 3C). The assay showed consistency in performance as measured

by the antibody titers of an in-house pooled convalescent reference standard (Figure 3D). The

GMT values for Delta variant between the fluorescence and HRP assays were comparable

(Supporting Figure S1). We adopted this method for in neutralization assays to compare both

neutralizing antibody titers of Delta and Omicron variants.

Omicron infection induces cross-protective antibodies to BA.1 and BA.2 sub-lineages

We collected follow-up samples in February and performed nucleocapsid (N) and RBD ELISA

to monitor antibody levels in samples from second and third waves. 11 of the 20 individuals had

detectable levels of N antibodies (cut off: 3 BAU/mL) in June 2021 suggesting that these were

infected with SARS-CoV-2 as the ChAdOx1 nCoV-19 vaccine does not generate N antibodies.

The GMT of N antibodies reduced from 2.9 (95% CI: 1.6, 5.2) in June 2021 to 1.8 (95% CI: 1.1.

2.9) in Dec 2021. However, the samples collected during the Omicron surge in Feb 2022 showed

an increase in N antibodies with a GMT of 7.6 (95% CI: 3.1, 18.7) with majority of the samples

turning positive (Figure 4A). Similar trends were observed with RBD antibodies where we

observed a 50% reduction in the RBD antibodies from a GMT of 197.3 (95% CI: 117.6, 331.0)

in June 2021 to 90.3 (95% CI: 44.1, 184.7) in Dec 2021. The samples from Omicron wave

showed a spike in RBD antibody titers to 586.0 (95% CI: 265.5, 1294) (Figure 4B). The

neutralizing antibody titers for Delta variant as measured by FRNT assay also showed about two-

fold reduction from a GMT of 262.1 (95% CI: 163.8, 419.4) in June 2021 to 119.9 (68.7, 209.2)

in Dec 2021 (Figure 4C). However, as expected from the ELISA titers, the neutralizing antibody

titers increased to 721.3 (95% CI: 407.7, 1276) in samples from Omicron wave indicating re-

infection in most of the individuals. As shown by our and other reports (8,10), the neutralizing

antibody titers for Omicron variant was drastically reduced at all time points (Figure 4D). The

GMT for Omicron variant was 30 (95% CI: 18.9, 47.8) in June 2021 samples which further

reduced to 24.3 (95% CI: 14.5, 40.7) by Dec 2021. Surprisingly, the samples from Omicron

surge showed relatively lower titer, a GMT of 183.6 (95% CI: 87.5, 385.2) as compared to 721.3

(95% CI: 407.7, 1276) for Delta variant suggesting that natural infection with Omicron variant

generates significantly higher levels of antibodies to Delta variant.

SARS-CoV-2 sequencing data from the National Capital Region (NCR), our study site,

showed co-occurrence of B.1.617.2 (Delta) and various AY.* (Delta plus) lineages during the

months of September 2021 to December 2021, wherein all AY lineages were more in circulation

than the parent B.1.617.2 lineage (Supplementary Figure S2). It is important to note that a rise in

the cases of Omicron lineages (B.1.529, BA.1 and BA.2) is observed from December 2021

onwards. This is concomitant with the arrival of Omicron variant in India and a gradual decrease

in circulation of Delta lineage. Delta variant was superseded by Omicron by January 2022.

Within Omicron lineages, cases of BA.2 sub-lineage increased/spread at a faster rate compared

to other Omicron lineages (BA.1 and B.1.529) in India (Supplementary Figure S2) which is

similar to reports from other countries. This is consistent with the observations that BA.2 lineage

has increased rates of transmission (12,13). We were able to isolate the BA.2 sub-lineage from a

clinical sample and performed neutralization assays in the subset of participants (n=14) who

were either RT-PCR positive in the ongoing Omicron surge or had symptomatic respiratory

infection but got no COVID-19 testing done. The GMT for BA.1 and BA.2 sub-lineages were

451.2 (95% CI: 255.2, 797.8) and 760.1 (95% CI: 493.1, 1172) and this difference was not

statistically significant as reported by others. Interestingly, all these samples had higher levels of

neutralizing antibodies for Delta variant (GMT 1302, 95% CI: 791.1, 2143) (Figure 4E). The

GMT of neutralizing antibodies in participants who remained uninfected at the time of sample

collection during the Omicron surge was 60.1 (95% CI: 32.9, 110), 58.6 (95% CI: 33.2, 103.6)

and 181.8 (95% CI: 89.6, 369) for BA.1, BA.2 and Delta variant respectively (Figure 4F) further

demonstrating that natural infection with Omicron variant led to potent induction of neutralizing

antibodies to the two sub-lineages and also to the Delta variant.

DISCUSSION

The samples for this study was conducted during the second and third wave of COVID-19 in

India during which the Delta and Omicron variants were the predominant circulating virus

strains. Our results are in concordance with previous observations in people vaccinated with the

mRNA vaccines (Pfizer-BioNTech) (14-16). We see a convincing association between the pre-

existing high antibody titers against both Alpha and Delta variants and protection from re-

infection by Delta variant in these individuals. Our data suggests that a $FRNT_{50}$ of 34 - 83 may

be sufficient to protect from Delta variant infection in younger adults. Interestingly, hybrid

immunity led to generation of neutralizing antibodies against the Alpha variant and the earlier

B.6 lineage which explains the reason for rapid decline in case load after July 2021 in India.

However, the same was not true for Omicron variant as only a subset of individuals had

detectable levels of antibodies to this VoC during early convalescence. Cohort data of patients

with mild COVID-19 infection has shown that RBD antibodies decay with a half-life of 69 days

(17). We observed a three-fold reduction in RBD antibody titers after six months, however,

neutralizing antibody levels reduced by 50% for Delta variant and most of the samples had no

neutralizing antibodies to Omicron after six months suggesting that waning neutralizing titers are

an important determinant of reinfections and may also contribute to increased susceptibility to

new VoCs that escape pre-existing humoral immunity. The high-throughput neutralizing

antibody assay we established enabled us to circumvent the challenges of estimating neutralizing

antibody titers for Omicron as it grew poorly and did not form distinct plaques or infectious foci

like Delta variant using our established methods. 14 out of 20 individuals were naturally infected

with the Omicron variant in the third wave and generated robust antibody responses. The level of

neutralizing antibodies was much higher to the Delta variant as compared to the BA.1 and BA.2

sub-lineages of Omicron variant in participants who were exposed to Omicron indicating that

natural infection with Omicron boosted antibodies to Delta variant. Our sequencing data suggests

that the BA.2 sub-lineage of the Omicron variant was the predominant circulating virus at the

time of the study and relatively higher levels of neutralizing antibodies to BA.2 as compared to

BA.1 further confirms that BA.2 may have been the infecting virus. We show that most people

got infected with Omicron variant and generated neutralizing antibodies against both BA.1 and

BA.2 sub-lineages indicating that exposure to any of the sub-lineages of Omicron would confer

cross-protection against other members of the lineage as reported by others (18). Interestingly,

higher titers of neutralizing antibodies were observed against the Delta variant which was no

longer in circulation indicating a broader cross-protective immune response most likely due to

conserved B-cell and T-cell epitopes (19-23) in the Omicron variant that could have triggered the

memory responses in people with hybrid immunity. As booster vaccination is offered to high-

risk individuals in India, natural infection with Omicron variant may have acted as a booster

eliciting cross-reacting antibodies across Omicron sub-lineages and other VoCs in young adults.

EXPERIMENTAL PROCEDURES

Human Ethics

The study was approved by the Institutional ethics committees for human research at ESIC

Hospital and Medical College (No.134/R/10/IEC/22/2021/02) and THSTI (THS 1.8.1/ (93)).

Informed consent was obtained from all the participants.

Human Samples

ChAdOx1 nCoV-19 cohort: Subjects (age 25-46) visiting ESIC Medical College & Hospital,

Faridabad for vaccination were enrolled into the study after obtaining written informed consent.

About 4 ml of whole blood was collected for serum preparation four weeks after first and second

dose of vaccination and a follow-up sample was collected after six months.

Nasopharyngeal/Oropharyngeal (NP/OP) swabs were collected from patients with symptoms of

COVID-19 infection. Total RNA was isolated to detect SARS-CoV-2 using COVIDsure

multiplex real time RT-PCR kit (Trivitron Healthcare) either at Employees State Insurance

Corporation (ESIC) Medical College & Hospital or at the bioassay laboratory Translational

Health Science and Technology Institute, Faridabad. Clinical presentations were mild to

moderate fever, dry cough, and loss of sense of smell and taste. All COVID-19 positive patients

were self-isolated and recovered without any need for clinical intervention or hospitalization. A

follow-up blood sample was collected after 3-4 weeks post-recovery in both second (May 2021)

and third wave (Feb 2022).

274   Cells and Viruses

275   Details of cells and viruses and virus isolation procedures has been described previously

276   (8,24,25) and described in detail in the supporting informaiton.

278   Whole genome sequencing

279   Three of the COVID-19 positive RNA samples from the second wave were sent for whole

280   genome sequencing as described in the supplementary information and the genome sequences

281   were deposited on the National centre for biotechnology database (MZ356901; MZ356904;

282   MZ646055).

284   Quantitative RBD and N ELISA

285   Recombinant spike protein receptor binding domain (RBD) ELISA was performed as described

286   earlier. Detailed method description is provided in previous reports (25).

288   Virus microneutralization assay

289   Virus microneutralization assay by focus reduction neutralization titer (FRNT) assay using

290   indicating virus isolates was performed as described earlier (25). For comparison with Omicron

291   variant, the assay was modified to a fluorescence-based detection. Detailed description of the

292   method is provided in supporting information.

Statistical analysis

295 Data was analysed and final graphs were prepared using GraphPad Prism (Version 9) software.

296 Statistical significance was estimated by ANOVA, Kruskal-Wallis test or Mann-Whitney test

297 with correction for multiple comparisons by Dunn's multiple comparison test.

Data availability

300 All the data are presented in this manuscript.

SUPPORTING INFORMATION

303 Detailed methods description is provided as supplementary information.

ACKNOWLEDGEMENTS

306 We thank all the members of bioassay lab, Amresh Kumar Singh and Maniram for technical

307 support. We thank Neha Garg, Shamsher Singh and Abitha Murali for data management and

308 other logistical support. We thank all the participants who consented for enrolment into the

309 study.

AUTHOR CONTRIBUTIONS

JS, HS, AA, BS, KP, PK, PC, PD, RM and PM performed experiments and analyzed the data.

NK and AKP coordinated the study at clinical site and contributed reagents. RP designed the

sequencing experiments and analyzed the data. GRM conceived the study, designed the

experiments, and analyzed the data. GRM wrote the manuscript. All authors have reviewed and

approved the final version of the manuscript.

FUNDING INFORMATION

This work was supported by the Department of Biotechnology (DBT) grants through IndCEPI

Mission (BT/MB/CEPI/2016) and Translational Research Program

(BT/PR30159/MED/15/188/2018). Funding support was also obtained from Global Immunology

and Immune Sequencing for Epidemic Response (INV-030592). RP acknowledges funding

support from IUSSTF (CLP-0033) and BMGF (CLP-0036). The funders had no role in study

design, data collection and interpretation or the decision to submit the work for publication.

CONFLICT OF INTEREST STATEMENT

The authors have declared that no conflict of interest exists.

REFERENCES

1. Suzuki, R., Yamasoba, D., Kimura, I., Wang, L., Kishimoto, M., Ito, J., Morioka, Y.,
Nao, N., Nasser, H., Uriu, K., Kosugi, Y., Tsuda, M., Orba, Y., Sasaki, M., Shimizu, R.,
Kawabata, R., Yoshimatsu, K., Asakura, H., Nagashima, M., Sadamasu, K., Yoshimura,
K., Suganami, M., Oide, A., Chiba, M., Ito, H., Tamura, T., Tsushima, K., Kubo, H.,
Ferdous, Z., Mouri, H., Iida, M., Kasahara, K., Tabata, K., Ishizuka, M., Shigeno, A.,
Tokunaga, K., Ozono, S., Yoshida, I., Nakagawa, S., Wu, J., Takahashi, M., Kaneda, A.,
Seki, M., Fujiki, R., Nawai, B. R., Suzuki, Y., Kashima, Y., Abe, K., Imamura, K.,
Shirakawa, K., Takaori-Kondo, A., Kazuma, Y., Nomura, R., Horisawa, Y., Nagata, K.,
Kawai, Y., Yanagida, Y., Tashiro, Y., Takahashi, O., Kitazato, K., Hasebe, H.,
Motozono, C., Toyoda, M., Tan, T. S., Ngare, I., Ueno, T., Saito, A., Butlertanaka, E. P.,
Tanaka, Y. L., Morizako, N., Sawa, H., Ikeda, T., Irie, T., Matsuno, K., Tanaka, S.,
Fukuhara, T., Sato, K., and The Genotype to Phenotype Japan, C. (2022) Attenuated
fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. *Nature*
2. Desai, D., Khan, A. R., Soneja, M., Mittal, A., Naik, S., Kodan, P., Mandal, A., Maher,
G. T., Kumar, R., Agarwal, A., Gowda, N. R., H, V., Kumar, P., Pandey, S., Pandey, R.
M., Kumar, A., Ray, A., Jorwal, P., Nischal, N., Choudhary, A., Brijwal, M., Madan, K.,

Lodha, R., Sinha, S., Dar, L., Wig, N., and Guleria, R. (2021) Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. *Lancet Infect Dis*

3. Mlcochova, P., Kemp, S., Dhar, M. S., Papa, G., Meng, B., Ferreira, I., Datir, R., Collier, D. A., Albecka, A., Singh, S., Pandey, R., Brown, J., Zhou, J., Goonawardane, N., Mishra, S., Whittaker, C., Mellan, T., Marwal, R., Datta, M., Sengupta, S., Ponnusamy, K., Radhakrishnan, V. S., Abdullahi, A., Charles, O., Chattopadhyay, P., Devi, P., Caputo, D., Peacock, T., Wattal, D. C., Goel, N., Satwik, A., Vaishya, R., Agarwal, M., Indian, S.-C.-G. C., Genotype to Phenotype Japan, C., Collaboration, C.-N. B. C.-., Mavousian, A., Lee, J. H., Bassi, J., Silacci-Fegni, C., Saliba, C., Pinto, D., Irie, T., Yoshida, I., Hamilton, W. L., Sato, K., Bhatt, S., Flaxman, S., James, L. C., Corti, D., Piccoli, L., Barclay, W. S., Rakshit, P., Agrawal, A., and Gupta, R. K. (2021) SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature*

4. Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., Prot, M., Gallais, F., Gantner, P., Velay, A., Le Guen, J., Kassis-Chikhani, N., Edriss, D., Belec, L., Seve, A., Courtellemont, L., Pere, H., Hocqueloux, L., Fafi-Kremer, S., Prazuck, T., Mouquet, H., Bruel, T., Simon-Loriere, E., Rey, F. A., and Schwartz, O. (2021) Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* **596**, 276-280

5. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Rathna Murugesan, D., Koundinya Desiraju, B., Kshetrapal, P., Pandey, R., Scaria, V., Kumar Malik, P., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., Ahmad Khan, N., Shaman, H., Ahmed, S., Kumar, R., Deshpande, S., Subramani, C., Wadhwa, N., Gupta, N., Pandey, A. K., Bhattacharya, J., Agrawal, A., Vrati, S., Bhatnagar, S., and Garg, P. K. (2021) Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. *The Lancet Infectious Diseases*

6. Yadav, P. D., Sapkal, G. N., Ella, R., Sahay, R. R., Nyayanit, D. A., Patil, D. Y., Deshpande, G., Shete, A. M., Gupta, N., Mohan, V. K., Abraham, P., Panda, S., and Bhargava, B. (2021) Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152. *bioRxiv*, 2021.2006.2005.447177

7. Dhar, M. S., Marwal, R., Radhakrishnan, V., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., Mishra, S., Whittaker, C., Fatihi, S., Datta, M., Singh, P., Sharma, U., Ujjainiya, R., Bhateja, N., Divakar, M. K., Singh, M. K., Imran, M., Senthivel, V., Maurya, R., Jha, N., Mehta, P., Vivekanand, A., Sharma, P., Arvinden, V., Chaudhary, U., Thukral, L., Flaxman, S., Bhatt, S., Pandey, R., Dash, D., Faruq, M., Lall, H., Gogia, H., Madan, P., Kulkarni, S., Chauhan, H., Sengupta, S., Kabra, S., Consortium, T. I. S.-C.-G., Gupta, R. K., Singh, S. K., Agrawal, A., and Rakshit, P. (2021) Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. *medRxiv*, 2021.2006.2002.21258076

8. Medigeshi, G., Batra, G., Murugesan, D. R., Thiruvengadam, R., Chattopadhyay, S., Das, B., Gosain, M., Ayushi, Singh, J., Anbalagan, A., Shaman, H., Pargai, K., Mehdi, F., Das, S. J., Kahlon, N., Singh, S., Kshetrapal, P., Wadhwa, N., Pandey, A. K., Bhatnagar, S., and Garg, P. K. (2022) Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by

Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid
Immunity) post 6-months. *medRxiv*, 2022.2001.2004.22268747

9.   Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A.,
Subbarao, K., Kent, S. J., Triccas, J. A., and Davenport, M. P. (2021) Neutralizing
antibody levels are highly predictive of immune protection from symptomatic SARS-
CoV-2 infection. *Nat Med* **27**, 1205-1211

10.   Dejnirattisai, W., Shaw, R. H., Supasa, P., Liu, C., Stuart, A. S., Pollard, A. J., Liu, X.,
Lambe, T., Crook, D., Stuart, D. I., Mongkolsapaya, J., Nguyen-Van-Tam, J. S., Snape,
M. D., Screaton, G. R., and Com, C. O. V. s. g. (2021) Reduced neutralisation of SARS-
CoV-2 omicron B.1.1.529 variant by post-immunisation serum. *Lancet*

11.   Meng, B., Ferreira, I. A. T. M., Abdullahi, A., Saito, A., Kimura, I., Yamasoba, D.,
Kemp, S. A., Goonawardane, N., Papa, G., Fatihi, S., Rathore, S., Ikeda, T., Toyoda, M.,
Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., Charles, O. J., Collaboration, C.-N. B.
C.-., Consortium, T. G. t. P. J., Consortium, E.-C., Smith, K. G. C., Bradley, J., Choi, J.,
Madissoon, E., Meyer, K., Mlcochova, P., Doffinger, R., Teichmann, S. A., James, L.,
Lee, J. H., Thukral, L., Sato, K., and Gupta, R. K. (2021) SARS-CoV-2 Omicron spike
mediated immune escape, infectivity and cell-cell fusion. *bioRxiv*,
2021.2012.2017.473248

12.   Lyngse, F. P., Kirkeby, C. T., Denwood, M., Christiansen, L. E., Mølbak, K., Møller, C.
H., Skov, R. L., Krause, T. G., Rasmussen, M., Sieber, R. N., Johannesen, T. B.,
Lillebaek, T., Fonager, J., Fomsgaard, A., Møller, F. T., Stegger, M., Overvad, M.,
Spiess, K., and Mortensen, L. H. (2022) Transmission of SARS-CoV-2 Omicron VOC
subvariants BA.1 and BA.2: Evidence from Danish Households. *medRxiv*,
2022.2001.2028.22270044

13.   Yamasoba, D., Kimura, I., Nasser, H., Morioka, Y., Nao, N., Ito, J., Uriu, K., Tsuda, M.,
Zahradnik, J., Shirakawa, K., Suzuki, R., Kishimoto, M., Kosugi, Y., Kobiyama, K.,
Hara, T., Toyoda, M., Tanaka, Y. L., Butlertanaka, E. P., Shimizu, R., Ito, H., Wang, L.,
Oda, Y., Orba, Y., Sasaki, M., Nagata, K., Yoshimatsu, K., Asakura, H., Nagashima, M.,
Sadamasu, K., Yoshimura, K., Kuramochi, J., Seki, M., Fujiki, R., Kaneda, A., Shimada,
T., Nakada, T.-a., Sakao, S., Suzuki, T., Ueno, T., Takaori-Kondo, A., Ishii, K. J.,
Schreiber, G., Consortium, T. G. t. P. J., Sawa, H., Saito, A., Irie, T., Tanaka, S.,
Matsuno, K., Fukuhara, T., Ikeda, T., and Sato, K. (2022) Virological characteristics of
SARS-CoV-2 BA.2 variant. *bioRxiv*, 2022.2002.2014.480335

14.   Ebinger, J. E., Fert-Bober, J., Printsev, I., Wu, M., Sun, N., Figueiredo, J. C., Eyk, J. E.
V., Braun, J. G., Cheng, S., and Sobhani, K. (2021) Prior COVID-19 Infection and
Antibody Response to Single Versus Double Dose mRNA SARS-CoV-2 Vaccination.
medRxiv

15.   Fraley, E., LeMaster, C., Geanes, E., Banerjee, D., Khanal, S., Grundberg, E.,
Selvarangan, R., and Bradley, T. (2021) Humoral immune responses during SARS-CoV-
2 mRNA vaccine administration in seropositive and seronegative individuals. *BMC Med*
19, 169

16.   Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach,
K. F., Bermudez-Gonzalez, M. C., Bielak, D. A., Carreno, J. M., Chernet, R. L., Eaker, L.
Q., Ferreri, E. D., Floda, D. L., Gleason, C. R., Hamburger, J. Z., Jiang, K., Kleiner, G.,
Jurczyszak, D., Matthews, J. C., Mendez, W. A., Nabeel, I., Mulder, L. C. F., Raskin, A.
J., Russo, K. T., Salimbangon, A. T., Saksena, M., Shin, A. S., Singh, G., Sominsky, L.

A., Stadlbauer, D., Wajnberg, A., and Simon, V. (2021) Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med* **384**, 1372-1374

17. Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., Nakao, C., Rayaprolu, V., Rawlings, S. A., Peters, B., Krammer, F., Simon, V., Saphire, E. O., Smith, D. M., Weiskopf, D., Sette, A., and Crotty, S. (2021) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* **371**

18. Yu, J., Collier, A.-r. Y., Rowe, M., Mardas, F., Ventura, J. D., Wan, H., Miller, J., Powers, O., Chung, B., Siamatu, M., Hachmann, N. P., Surve, N., Nampanya, F., Chandrashekar, A., and Barouch, D. H. (2022) Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. *medRxiv*, 2022.2002.2006.22270533

19. Angkasekwinai, N., Niyomnaitham, S., Sewatanon, J., Phumiamorn, S., Sukapirom, K., Senawong, S., Mahasirimongkol, S., Toh, Z. Q., Umrod, P., Somporn, T., Chumpol, S., Ritthitham, K., Jantraphakorn, Y., Srisutthisamphan, K., and Chokephaibulkit, K. (2022) The immunogenicity against variants of concern and reactogenicity of four COVID-19 booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series. *medRxiv*, 2021.2011.2029.21266947

20. Gao, Y., Cai, C., Grifoni, A., Muller, T. R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L., Osterborg, A., Bergman, P., Chen, P., Olsson, A., Sandberg, J. K., Weiskopf, D., Price, D. A., Ljunggren, H. G., Karlsson, A. C., Sette, A., Aleman, S., and Buggert, M. (2022) Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. *Nat Med*

21. GeurtsvanKessel, C. H., Geers, D., Schmitz, K. S., Mykytyn, A. Z., Lamers, M. M., Bogers, S., Scherbeijn, S., Gommers, L., Sablerolles, R. S. G., Nieuwkoop, N. N., Rijsbergen, L. C., van Dijk, L. L. A., de Wilde, J., Alblas, K., Breugem, T. I., Rijnders, B. J. A., de Jager, H., Weiskopf, D., van der Kuy, P. H. M., Sette, A., Koopmans, M. P. G., Grifoni, A., Haagmans, B. L., and de Vries, R. D. (2022) Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients. *Sci Immunol*, eabo2202

22. Keeton, R., Tincho, M. B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S., Bernstein, M., Karim, F., Madzorera, S. V., Moyo-Gwete, T., Mennen, M., Skelem, S., Adriaanse, M., Mutithu, D., Aremu, O., Stek, C., du Bruyn, E., Van Der Mescht, M. A., de Beer, Z., de Villiers, T. R., Bodenstein, A., van den Berg, G., Mendes, A., Strydom, A., Venter, M., Giandhari, J., Naidoo, Y., Pillay, S., Tegally, H., Grifoni, A., Weiskopf, D., Sette, A., Wilkinson, R. J., de Oliveira, T., Bekker, L. G., Gray, G., Ueckermann, V., Rossouw, T., Boswell, M. T., Bihman, J., Moore, P. L., Sigal, A., Ntusi, N. A. B., Burgers, W. A., and Riou, C. (2022) T cell responses to SARS-CoV-2 spike cross-recognize Omicron. *Nature*

23. Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., Methot, N., Bloom, N. I., Goodwin, B., Phillips, E., Mallal, S., Sidney, J., Filaci, G., Weiskopf, D., da Silva Antunes, R., Crotty, S., Grifoni, A., and Sette, A. (2022) SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. *Cell* **185**, 847-859 e811

24. Anantharaj, A., Gujjar, S., Kumar, S., Verma, N., Wangchuk, J., Khan, N. A., Panwar, A., Kanakan, A., A, V., Vasudevan, J. S., Das, A., Pandey, A. K., Pandey, R., and

Medigeshi, G. R. (2020) Kinetics of viral load, immunological mediators and characterization of a SARS-CoV-2 isolate in mild COVID-19 patients during acute phase of infection. *medRxiv*, 2020.2011.2005.20226621

25. Das, S., Singh, J., Shaman, H., Singh, B., Anantharaj, A., Sharanabasava, P., Pandey, R., Lodha, R., Pandey, A. K., and Medigeshi, G. R. (2022) Antibody response after a single dose of BBV152 vaccine negatively correlates with pre-existing antibodies and induces a significant but low levels of neutralizing antibodies to Omicron variant. *medRxiv*, 2022.2002.2007.22270612

FIGURE LEGENDS

Figure 1: Quantitation of RBD antibodies by ELISA. Serum levels of antibodies against SARS-CoV-2 RBD was estimated by quantitative ELISA in study participants after one dose of ChAdOx1 nCoV-19 vaccine. (A) Participants were sub-grouped based on prior history of infection as uninfected, infected. Four non-vaccinated individuals served as controls. (B) Pre-infection RBD antibody titers in participants who got infected with COVID-19 after few days of receiving first dose of vaccine. Dotted line indicates the limit of quantitation (C) RBD antibody titers in samples collected before and after infection in participants who were COVID-19-positive and (D) RBD antibody titers from samples collected at the same time-point from participants who did not get infected with COVID-19 during the second wave. Data was expressed as BAU/ml (international units) as the secondary reference reagent was calibrated against the WHO international reference standard. P values are indicated by - * $p<0.05$; ** $p<0.01$; *** $p < 0.001$; ns - not significant.

Figure 2: Estimation of 50% virus neutralization antibody titers by FRNT assay. (A-C) $FRNT_{50}$ titers for the three indicated virus lineages in paired samples collected prior to and after infection in samples collected from participants who were RT-PCR positive during the second wave. (D-F) $FRNT_{50}$ titers of samples from participants who were not positive for

COVID-19 during the second wave. (G) RBD-ELISA titers in paired samples collected six

months post-vaccination. (H) $FRNT_{50}$ titers in paired samples for Delta variant. BAU: Binding

Antibody Units. P values are indicated by - * p<0.05; ** p<0.01; *** p < 0.001; ns - not

significant.

Figure 3: Growth characteristics of Omicron variant and establishment of FRNT assay:

(A) Calu-3 or Vero E6 cells were incubated with 10-fold serial dilution of Omicron (BA.1)

variant to determine virus titers by plaque assay. Plates were fixed at 24 and 48 h pi and stained

with crystal violet. (B) Vero E6 cells were infected with a pre-determined dilution of Omicron

variant for focus-forming unit assay using anti-spike and anti-nucleocapsid antibodies followed

by HRP-conjugated secondary antibody. Foci were developed using TrueBlue substrate. (C)

Vero E6 cells were infected with a pre-determined dilution of Omicron variant for focus-forming

unit assay using anti-spike and anti-nucleocapsid antibodies followed by Alexa488-conjugated

secondary antibody. Foci were visualized under fluorescence channel. (D) FRNT assay using

fluorescence method to determine the neutralization titers of antibodies against the Delta and

Omicron variants. 50% neutralization titer of antibodies (NT_{50}) is given from at least five

experimental replicates (Mean $\pm$ SD).

Figure 4: Omicron infection induces cross-protective antibodies: (A) Binding antibodies to

nucleocapsid (N) and (B) RBD were estimated by quantitative ELISA for the three bleeds post

vaccination as indicated (n=20). (C) Neutralizing antibody titers to Delta variant and (D)

Omicron variant was determined in the same bleeds by FRNT assay. (E) Neutralizing antibody

titers to the BA.1 and BA.2 sub-lineages were determined in samples from participants (n=14)

that were RT-PCR positive or (F) remained uninfected (n=6) during the third wave. ns: not

significant. * P<0.05;** P<0.01;*** P<0.001;**** P<0.0001.

Table 1: Virus neutralization titers post single-dose vaccination with or without
prior history of SARS-CoV-2 infection.

Lineage tested in FRNT assay	B.6		B.1.1.7		B.1.617.2	
Prior SARS-CoV-2 infection	+*	-	+	-	+	-
Geometric mean	1873	110.2	1056	53.82	783.7	50.47
Lower 95% CI	366.4	70.40	133.1	36.83	132.2	31.59
Upper 95% CI	9574	172.5	8382	78.64	4646	80.64
P value#	0.0097		0.0188		0.0094	

537 * N = 6 for prior infection (+) and N=12 for no prior infection (-)

538 # P value determined by Mann-Whitney test

Figure 1

A ELISA titers post-first-dose

COVID-19 : − + NV
(2020)

B Pre-infection titers

COVID-19 : + −
(2021)

C **D**

Figure 2

Infected in 2021

A ** B.6

B *** B.1.1.7

C *** B.1.617.2

Uninfected in 2021

D ns

E ns

F ns

Seropositive prior to vaccination

Seronegative prior to vaccination

G *

H ns

Figure 3

A

	Calu-3		Vero E6	
	Omicron	Delta	Omicron	Delta

10⁻² 10⁻³ 10⁻⁴ 10⁻⁵ — 24 h pi

10⁻² 10⁻³ 10⁻⁴ 10⁻⁵ — 48 h pi

B **C** **D**

anti-Spike   anti-N   anti-Spike   anti-N

B.1.617.2

B.1.1.529

Delta NT$_{50}$ = 844 ± 111.3
Omicron NT$_{50}$ = 106.1 ± 26.8

% Neutralization

Serum dilution (log$_{10}$)

Figure 4